Daehan Nupharm대한뉴팜
054670 · KOSDAQ · ₩054670 · 대한뉴팜
- Market cap
- ₩73B
- Enterprise value
- ₩136B
- P/E
- 3.1×
- P/B
- 0.5×
- Dividend yield
- 2.0%
- ROE
- 15.8%
- Net margin
- 11.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−35.4% from the high
₩5,010Today: ₩5,010 – ₩5,110₩7,900
Returns
- 1W−1.7%
- 1M−6.9%
- 3M−8.9%
- 6M−28.3%
- YTD−22.4%
- 1Y−22.7%
- Volume today
- 37,734
- 2.8× the 20-day average
- Traded today
- ₩190M
- Listed shares
- 14,354,920
- EPS (12 months)
- ₩1,638
- Earnings yield 32.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Warming up- BuzzRisingBuzz 59: heavy trading.
- MomentumWeak-5.7% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Daehan Nupharm stock overview
Daehan Nupharm (대한뉴팜, KRX: 054670) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells human pharmaceuticals, including prescription drugs for chronic conditions such as hypertension, dyslipidemia, diabetes and peptic ulcers, as well as non-covered injectables for obesity and wellness, and veterinary medicines for livestock and pets. Its shares closed at ₩5,100 on Oct 30, 2026, down 0.20% on the day, giving it a market value of ₩73B.
Key facts
- Market cap
- ₩73B
- Sector
- Biotech & Pharma
- Latest price change
- −0.20%
- As of
- Oct 30, 2026
- Main business
- The company develops, manufactures and sells human pharmaceuticals, including prescription drugs for chronic conditions such as hypertension, dyslipidemia, diabetes and peptic ulcers, as well as non-covered injectables for obesity and wellness, and veterinary medicines for livestock and pets.
Quick answers about Daehan Nupharm
- What does Daehan Nupharm do?
- The company develops, manufactures and sells human pharmaceuticals, including prescription drugs for chronic conditions such as hypertension, dyslipidemia, diabetes and peptic ulcers, as well as non-covered injectables for obesity and wellness, and veterinary medicines for livestock and pets. It also pursues vaccines, health functional foods, and stem-cell-based bio businesses, and reports overseas sales alongside domestic ones.
- What is the market cap of Daehan Nupharm?
- The market capitalisation of Daehan Nupharm was ₩73B at the close on Oct 30, 2026.
- Who are the largest shareholders of Daehan Nupharm?
- According to the latest official filings, the largest reported holders are Lee Wan-jin (40.99%, as of Oct 1, 2026); Lee Won-seok (8.27%, as of May 29, 2026); Dimensional Emerging Core Equity Market ETF (0.01%, as of Jul 31, 2026).
- When is the next earnings report from Daehan Nupharm?
- Korean companies rarely announce results dates in advance. Based on when Daehan Nupharm filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 13, 2026.
Company profile
The company develops, manufactures and sells human pharmaceuticals, including prescription drugs for chronic conditions such as hypertension, dyslipidemia, diabetes and peptic ulcers, as well as non-covered injectables for obesity and wellness, and veterinary medicines for livestock and pets. It also pursues vaccines, health functional foods, and stem-cell-based bio businesses, and reports overseas sales alongside domestic ones.
Written by AI from the company's latest annual report.
- Korean name
- 대한뉴팜
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이원석
- Founded
- Oct 1984
- Listed
- Feb 2002
- Listed shares
- 14,354,920
- Fiscal year ends
- Month 12
- Website
- www.dhnp.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- 5%+ holding reportOct 1, 2026
- Amended: Audit report submittedAug 28, 2026
- Amended: Annual report (Dec 2025)Aug 28, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportAug 7, 2026
Titles in Korean until English translations are added.
Also known as: Daehan Nupharm / 대한뉴팜 / 054670 / KRX:054670
Source: KRX statistical information